Status:
COMPLETED
Myoglobin Removal by High Cut-off CVVHD
Lead Sponsor:
Vantive Health LLC
Collaborating Sponsors:
Gambro Dialysatoren GmbH
Baxter Healthcare Corporation
Conditions:
Rhabdomyolysis
Renal Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A high cut-off dialyzer (septeX) is tested for the removal of myoglobin which is not efficiently removed by standard high flux dialysis membranes. Hypothesis: The high cut-off dialyzer (septeX) can re...
Detailed Description
Excess myoglobin in the circulation is a causative pathogenetic factor of rhabdomyolysis associated with acute kidney injury (AKI). The rapid elimination of myoglobin by standard dialysis membranes is...
Eligibility Criteria
Inclusion
- Acute Rhabdomyolysis
- placed central venous catheter
- Indication for RRT due to Serum CK level \> 5000 u/L
- Age ≥ 18 years
- Signed ICF
Exclusion
- End stage CKD (dialysis dependent) renal failure before manifestation of rhabdomyolysis
- Pregnancy or lactation
- Palliative treatment
- Participation in other clinical studies
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01467180
Start Date
November 1 2011
End Date
May 1 2014
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik für Anästhesiologie, Intensivmedizin, Uni-Klinikum
Frankfurt am Main, Hesse, Germany, 60590